These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30711833)

  • 1. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
    Li C; Han X; Yan Q; Ji Y; Zhang R; Yuan D; Yang F; Wang J; Wu M; Zhou J
    J Med Chem; 2024 Mar; 67(5):3419-3436. PubMed ID: 38385428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance.
    Chai X; Hu XP; Wang XY; Wang HT; Pang JP; Zhou WF; Liao JN; Shan LH; Xu XH; Xu L; Xia HG; Hou TJ; Li D
    Acta Pharmacol Sin; 2023 Jul; 44(7):1500-1518. PubMed ID: 36639570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
    Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Puhr M; Eigentler A; Handle F; Hackl H; Ploner C; Heidegger I; Schaefer G; Brandt MP; Hoefer J; Van der Pluijm G; Klocker H
    Oncogene; 2021 Apr; 40(17):3087-3100. PubMed ID: 33795839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel androgen receptor antagonists via molecular modeling.
    Zhao C; Choi YH; Khadka DB; Jin Y; Lee KY; Cho WJ
    Bioorg Med Chem; 2016 Feb; 24(4):789-801. PubMed ID: 26780832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the gossypol derivatives as androgen receptor inhibitor.
    Zhang R; Wu M; Cao T; Luo K; Huang F; Zhang R; Huang Z; Zhou J; Wang Y; Zhu S
    Bioorg Med Chem Lett; 2022 Nov; 75():128952. PubMed ID: 36031018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
    Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
    Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.
    Sakellakis M; Flores LJ
    Medicine (Baltimore); 2022 Jul; 101(29):e29716. PubMed ID: 35866830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
    Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
    Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
    Xu X; Ge R; Li L; Wang J; Lu X; Xue S; Chen X; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():1325-1344. PubMed ID: 29117897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
    Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation.
    Zhang D; Asnake S; Zhang J; Olsson PE; Zhao G
    Chem Biol Drug Des; 2018 Jun; 91(6):1113-1124. PubMed ID: 29388326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.